Sepsis-associated takotsubo cardiomyopathy can be reversed with levosimendan

American Journal of Emergency Medicine

Volumn 30, Issue 5, 2012, Pages 832.e5-832.e7

  Karvouniaris, Marios ^a   Papanikolaou, John ^a   Makris, Demosthenes ^a   Zakynthinos, Epameinondas ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; DOBUTAMINE; GLUCOSE; HEMOGLOBIN; HYDROCORTISONE; LACTIC ACID; LEVOSIMENDAN; NORADRENALIN;

ADULT; ARTICLE; BLOOD CELL COUNT; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEART FUNCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PYELONEPHRITIS; SEPSIS; TAKOTSUBO CARDIOMYOPATHY; THORAX RADIOGRAPHY;

EID: 84861854176     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2011.02.030     Document Type: Article

References (13)

1. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Intensive Care Med 2008;34:17-60.
2. Morgan P, Al-Subaie N, Rhodes A. Minimally invasive cardiac output monitoring. Curr Opin Crit Care 2008;14:322-6. (Pubitemid 351667918)
3. Palacio C, Nugent K, Alalawi R, Cevik C. Severe reversible myocardial depression in a patient with Pseudomonas aeruginosa sepsis suggesting tako-tsubo cardiomyopathy. Int J Cardiol 2009;135(1):e16-9.
4. Geng S, Mullany D, Fraser JF. Takotsubo cardiomyopathy associated with sepsis due to Streptococcus pneumoniae pneumonia. Crit Care Resusc 2008;10(3):231-4.
5. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202. (Pubitemid 34804646)
6. Padayachee L. Levosimendan: the inotrope of choice in cardiogenic shock secondary to takotsubo cardiomyopathy. Heart Lung Circ 2007;16:S65-70. (Pubitemid 47233292)
7. De Santis V, Vitale D, Tritapepe L, Greco C, Pietropaoli P. Use of levosimendan for cardiogenic shock in a patient with the apical ballooning syndrome. Ann Intern Med 2008;149:365-7.
8. Antonini M, Stazi GV, Cirasa MT, Garotto G, Frustaci A. Efficacy of levosimendan in takotsubo-related cardiogenic shock. Acta Anaesthesiol Scand 2010;54(1):119-20.
9. Maeder M, Fehr T, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction. Chest 2006;129:1349-66.
10. Pilgrim TM, Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: a systematic review. Int J Cardiol 2008;124:283-92. (Pubitemid 351313913)
11. Akashi YJ, Goldstein DS, Barbaro G, Ueyama T. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation 2008;118:2754-62.
12. Wong CP, Wong CP, Jim MH, Chan AO, Chau EM, Chow WH. Iatrogenic tako-tsubo cardiomyopathy. Int J Cardiol 2008;125(1): e16-8. Epub 2007 Mar 29.
13. Behrends M, Peters J. The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med 2003;10:1802-7. Epub 2003 Jul 17.